Hematologic Malignancy

Mature B-Cell Neoplasm

HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items

NCIt: C27910
DOID: 706

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Literature

Linked publications (184)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 26–50 of 184 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Innate immune dysregulation in multiple myeloma: molecular basis and mechanistic interventions.
Gang Wang, Hanlin Gao, Tianyi Xie et al. · Int Immunopharmacol · Sep 15, 2026 · PMID 42314557 · candidate dictionary pubmed
Imaging B cell maturation antigen in multiple myeloma.
Yangmeihui Song, Wenyu Song, Weibo Cai · J Clin Invest · Sep 15, 2026 · PMID 42741935 · candidate dictionary pubmed
A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging.
Tingfei Gu, Zhao Chen, Bo Tang et al. · J Clin Invest · Sep 15, 2026 · PMID 42378054 · candidate dictionary pubmed
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study.
Attaya Suvannasankha, Mengying Li, Omonefe Omofuma et al. · Clin Cancer Res · Sep 15, 2026 · PMID 42283723 · candidate dictionary pubmed
Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma.
Rafael R Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads et al. · Cancer Res · Sep 15, 2026 · PMID 42233980 · candidate dictionary pubmed
Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.
Henrik Niklas, Anna Bold, Simon Völkl et al. · Ann Hematol · Sep 15, 2026 · PMID 42747560 · candidate dictionary pubmed

Outcomes of stereotactic radiosurgery for spine multiple myeloma-a systematic review.

Muhammad Izhar, Yusuke S Hori, Ahed H Kattaa et al. · Neurosurg Rev · Sep 14, 2026 · PMID 42733030 · candidate dictionary pubmed

Multiple Myeloma-Derived Cellular Lipids Enhance Targeting and Efficacy of Nanoliposome Formulations In Vitro.

Mathew Amorin, Christina Tran, Eden Park et al. · Int J Mol Sci · Sep 13, 2026 · PMID 42794583 · candidate dictionary pubmed

Treatment Decisions in Multiple Myeloma.

Tarek H Mouhieddine, Kenneth C Anderson · N Engl J Med · Sep 10, 2026 · PMID 42715563 · candidate dictionary pubmed

Product-intrinsic NF-κB-driven transcriptional programs connote durability of CAR-T response in multiple myeloma.

Jerald D Noble, Barbara C Peixoto, Meghan A Menges et al. · Blood · Sep 10, 2026 · PMID 42275255 · candidate dictionary pubmed

Adapting a mental health program for people with multiple myeloma and smouldering myeloma: a consumer-informed feasibility study.

Natalie Tuckey, Matthew Iasiello, Melissa Cantley et al. · Support Care Cancer · Sep 8, 2026 · PMID 42706438 · candidate dictionary pubmed

Heestermans R, Olsen C, Ameli S, et al. Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma. Blood Adv. 2025;9(16):4306-4310.

· Blood Adv · Sep 8, 2026 · PMID 42664001 · candidate dictionary pubmed

TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma.

Benjamin Podvin, Holly Lee, Rémi Tilmont et al. · Blood Adv · Sep 8, 2026 · PMID 42418388 · candidate dictionary pubmed

Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement.

Alexander Xiao, Saurabh Zanwar, Yi Lin et al. · Blood Adv · Sep 8, 2026 · PMID 42348786 · candidate dictionary pubmed

Comment on "Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?".

Manish R Bhise, Akshay Akotkar, Shweta Bhandari et al. · J Cancer Res Clin Oncol · Sep 7, 2026 · PMID 42706433 · candidate dictionary pubmed

Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma.

Yating Li, Lihui Shi, Wenqiang Yan et al. · Leukemia · Sep 7, 2026 · PMID 42706314 · candidate dictionary pubmed

Myeloma engraftment suppresses osteocytic ossification signatures rescued by loading in mice and reveals predictors of patient outcome.

Fani Ziouti, Muhammad Azeem, Maximilian Rummler et al. · Bone · Sep 7, 2026 · PMID 42705405 · candidate dictionary pubmed

Activating a novel cell death pathway to target PI-resistant multiple myeloma and enhance immunogenic cell death.

Xinyun Zhang, Zhiming Wang, Yilei Shi et al. · Apoptosis · Sep 7, 2026 · PMID 42704369 · candidate dictionary pubmed

Machine Learning-Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma.

Kai Wang, Chenfei Zhao, Jingru Shi et al. · Cancer Sci · Sep 6, 2026 · PMID 42702361 · candidate dictionary pubmed

MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma.

Daizo Yokoyama, Daisuke Minakata, Shin-Ichiro Fujiwara et al. · Leuk Lymphoma · Sep 6, 2026 · PMID 42702057 · candidate dictionary pubmed

Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma.

Wenwen Cheng, Silvia Gaggero, Lama Hasan Bou Issa et al. · Biomark Res · Sep 5, 2026 · PMID 42701201 · candidate dictionary pubmed

Newest glue degrader nabs multiple myeloma approval.

Asher Mullard · Nat Rev Drug Discov · Sep 4, 2026 · PMID 42697955 · candidate dictionary pubmed

Genomic staging in myeloma: The need for population-specific validation.

Curtis Marcoux, Alfredo De la Torre, Darrell White · Br J Haematol · Sep 4, 2026 · PMID 42695571 · candidate dictionary pubmed

Integrating Palliative Care into Relapsed/Refractory Multiple Myeloma in the Immunotherapy Era: A Narrative Review.

Muhanad Alzahrani, Zaid Musaad Alsharif, Ziyad Alzahrani · J Pain Palliat Care Pharmacother · Sep 3, 2026 · PMID 42693623 · candidate dictionary pubmed

FASTINA - protocol for a randomised feasibility trial of time-restricted eating to improve response to multiple myeloma therapy.

Anna Franziska Hamm, Jan Vorwerk, Mona Maria Merz et al. · Pilot Feasibility Stud · Sep 3, 2026 · PMID 42693457 · candidate dictionary pubmed